Estimation of ‘spectrum value’: A discrete choice experiment to investigate the willingness-to-pay for narrow-spectrum based on other antimicrobial characteristics
While narrow-spectrum antimicrobials are preferred for targeted therapy by health practitioners with AMS expertise, price significantly influenced drug choice. Willingness-to-pay values reflect the knowledge and experience of AMS experts who are best-placed to gauge the opportunity costs of paying more for narrow-spectrum antimicrobials. These findings can inform the quantification of spectrum-value for health-system funding decisions.
Authors
- JD Turnidge
- Jennie Louise
- Jonathan Karnon
- Gang Chen
- Tracy L. Merlin
Institutions
- The University of Melbourne (AU)
- Flinders University (AU)
- Women's and Children's Hospital (AU)
- Women's & Children's Health Research Institute (AU)
- Caulfield Hospital (AU)
- SA Health (AU)
- South Australian Health and Medical Research Institute (AU)
- Melbourne Health (AU)
- Monash University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Applied Health Economics and Health Policy
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1007/s40258-025-01025-z
- Primary Topic
- Economic and Environmental Valuation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government